Form 8-K

8-K — Hims & Hers Health, Inc.

Accession: 0001773751-26-000161

Filed: 2026-08-10

Period: 2026-08-10

CIK: 0001773751

SIC: 8011 (SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — hims-20260810.htm (Primary)

EX-99.1 (hims-20260630x8xkearningsr.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: hims-20260810.htm · Sequence: 1

hims-20260810

0001773751false00017737512026-08-102026-08-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 10, 2026

HIMS & HERS HEALTH, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-38986

98-1482650

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2269 Chestnut Street, #523

94123

San Francisco

California

(Zip Code)

(Address of principal executive offices)

Registrant’s telephone number, including area code: (415) 851-0195

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol

Name of each exchange on which registered

Class A common stock, $0.0001 par value

HIMS

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.

Results of Operations and Financial Condition.

On August 10, 2026, Hims & Hers Health, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference in this Item 2.02.

The information in this Current Report on Form 8-K and Exhibit 99.1 is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release dated August 10, 2026

104

Cover Page Interactive Data file (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HIMS & HERS HEALTH, INC.

DATE: August 10, 2026

By:

/s/ Oluyemi Okupe

Oluyemi Okupe

Chief Financial Officer

(Principal Financial Officer)

EX-99.1

Filename: hims-20260630x8xkearningsr.htm · Sequence: 2

Document

Hims & Hers Health, Inc. Reports Second Quarter 2026 Financial Results

Revenue of approximately $753 million, up 38% year-over-year in Q2 2026

Subscribers grew to nearly 2.9 million, up 19% year-over-year in Q2 2026

Raises full year 2026 revenue guidance to a range of $3.1 billion to $3.3 billion and updates Adjusted EBITDA guidance to a range of $275 million to $325 million

SAN FRANCISCO, August 10, 2026 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading global health and wellness platform, today announced financial results for the second quarter ended June 30, 2026.

“Hims & Hers is delivering a world-class health experience at a global scale and a reasonable price for the nearly 3 million people who rely on us for access to care. We’re proving, quarter after quarter, that helping people feel great and delivering strong results aren’t mutually exclusive,” said Andrew Dudum, co-founder and CEO. “We have never been better positioned to move faster or go further than we are today. As we rebuild the consumer health experience from the ground up with a doctor-led AI clinical engine, the depth and breadth of our relationships with customers worldwide has never been greater. Every quarter, we raise the standard for what care should look like everywhere: high-quality, personal, and accessible.”

“Our second quarter results were defined by a significant re-acceleration in our growth profile and the continued expanding reach of our platform,” said Yemi Okupe, Chief Financial Officer. “Domestic revenue growth accelerated to 16% year-over-year, and our international business grew more than 17-fold, strengthened by the close of our Eucalyptus acquisition in June. We expect our domestic business to continue accelerating through the second half of the year. This momentum, combined with the meaningful efficiencies we're generating from our investments in AI and technology, positions us to make access to high touch, comprehensive care more affordable for our customers while also significantly expanding our reach internationally. As a result, we are raising our 2026 revenue outlook and building increased conviction in our 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA.”

Key Business Metrics

(In Thousands, Except for Monthly Revenue per Average Subscriber, Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

% Change

2026

2025

% Change

Subscribers (end of period)

2,891

2,439

2,891

2,439

Monthly Revenue per Average Subscriber

Revenue

(In Thousands, Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

% Change

2026

2025

% Change

United States Revenue

621,830

537,286

1,151,739

1,115,978

Rest of the World Revenue

131,384

7,547

1,641

209,579

14,865

1,310

Total revenue

753,214

544,833

1,361,318

1,130,843

Second Quarter 2026 Financial Highlights

•Revenue was $753.2 million for the second quarter of 2026 compared to $544.8 million for the second quarter of 2025, an increase of 38% year-over-year.

•Gross margin was 64% for the second quarter of 2026 compared to 76% for the second quarter of 2025.

•Net loss was $86.3 million for the second quarter of 2026 compared to net income of $42.5 million for the second quarter of 2025.

•Adjusted EBITDA was $60.3 million for the second quarter of 2026 compared to $82.2 million for the second quarter of 2025.

•Net cash (used in) operating activities was $(35.9) million for the second quarter of 2026 compared to $(19.1) million for the second quarter of 2025.

•Free Cash Flow was $(68.2) million for the second quarter of 2026 compared to $(69.4) million for the second quarter of 2025.

Reconciliations of Adjusted EBITDA and Free Cash Flow, non-GAAP measures, to net (loss) income and net cash (used in) provided by operating activities, respectively, their most comparable financial measures under generally accepted accounting principles in the United States (“U.S. GAAP”), have been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA and Free Cash Flow is also included below under the heading “Non-GAAP Financial Measures”.

Financial Outlook

Hims & Hers is providing the following guidance:

For the third quarter 2026, we expect:

•Revenue of $880 million to $900 million.

•Adjusted EBITDA of $75 million to $95 million, reflecting an Adjusted EBITDA margin of 9% to 11%.

For the full year 2026, we expect:

•Revenue of $3.1 billion to $3.3 billion.

•Adjusted EBITDA of $275 million to $325 million, reflecting an Adjusted EBITDA margin of 9% to 10%.

The guidance provided above constitutes forward-looking statements and actual results may differ materially. Refer to the “Cautionary Note Regarding Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

We have relied upon the exception in Item 10(e)(1)(i)(B) of Regulation S-K and have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net income or loss, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net income or loss. See “Non-GAAP Financial Measures” for additional important information regarding Adjusted EBITDA.

Conference Call

Hims & Hers will host a conference call to review the second quarter 2026 results on August 10, 2026, at 5:00 p.m. ET. The conference call can be accessed by dialing +1 (833) 461-5787 for U.S. participants and +1 (585) 542-9983 for international participants, and referencing conference ID #782 611 911. A live audio webcast will be available online at investors.hims.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link.

About Hims & Hers Health, Inc.

Hims & Hers is the leading global health and wellness platform on a mission to help the world feel great through the power of better health.

We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.

For more information, please visit investors.hims.com.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assumes,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,” “continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “outlook,” “opportunity,” “confidence,” “foundation,” “groundwork,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line revenue growth and profitability and our ability to attain our 2026 and long-term financial and operational targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, investments in innovation, the solutions accessible on our platform, the markets accessible on our platform, and our infrastructure, and the underlying assumptions with respect to the foregoing; potential strategic investments, partnerships, or collaborations, and the expected timing or outcome of any such investments, partnerships, or collaborations; statements relating to events and trends relevant to us, including with respect to our regulatory environment, financial condition, results of operations, short- and long-term business operations, objectives, strategy, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, brand development, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies and leverage (including our fulfillment capabilities), the effect of any pricing decisions; changes in our product or offering mix, and the timing and market acceptance of any new products or offerings; the timing and anticipated effect of any pending or recently completed acquisitions; the success and utility of our business model; our market opportunity; our ability to scale our business and expand internationally; the growth of certain of our specialties; our ability to innovate on and expand the scope of our offerings and experiences, including through the use of diagnostics, data analytics and artificial intelligence; our ability to reinvest into the customer experience; and our ability to comply with the extensive, complex and evolving legal and regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations, and the effect or outcome of litigation or governmental actions or statements in relation to any such legal and regulatory requirements. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this press release are based on our current expectations, assumptions, and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission (the “Commission”).

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this press release are made only as of August 10, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our most

recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.

Key Business Metrics

Our consolidated revenue primarily comprises online sales of health and wellness products through our websites and mobile applications, including prescription and non-prescription products, as well as services, primarily consisting of medical consultation services, membership-based access, post-consultation service support, and delivery of laboratory testing results, as applicable. Our online sales are net of refunds, credits, and chargebacks, and include revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve. A substantial majority of our online sales are subscription-based, where customers agree to be billed on a recurring basis to have products and services automatically delivered to them. This revenue also includes sales from customers who have made one-time purchases.

“United States Revenue” represents the sales of products and services by our consolidated legal entities operating within jurisdictions located inside of the United States.

“Rest of the World Revenue” represents the sales of products and services by our consolidated legal entities operating within jurisdictions located outside of the United States.

“Subscribers” are customers who have one or more “Subscriptions” pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence. The Subscription billing cadence is typically defined as a number of days (for example, billed every 30 days or every 90 days), which are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscribers can cancel or snooze Subscriptions in between billing periods to stop receiving additional products and/or services and can reactivate Subscriptions to continue receiving additional products and/or services. Customers who have made one-time purchases are not considered Subscribers.

“Monthly Revenue per Average Subscriber” is defined as total revenue divided by “Average Subscribers”, which amount is then further divided by the number of months in a period. “Average Subscribers” are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In Thousands, Except Share and Per Share Data, Unaudited)

June 30, 2026

December 31, 2025

Assets

Current assets:

Cash and cash equivalents

609,811

228,616

Short-term available-for-sale investments

231,237

348,876

Receivables, net

375,291

32,149

Inventory

87,781

80,128

Prepaid expenses and other current assets

80,493

77,869

Total current assets

1,384,613

767,638

Long-term available-for-sale investments

—

351,263

Goodwill

1,101,720

278,325

Property, equipment, and software, net

364,215

311,930

Intangible assets, net

422,809

196,116

Operating lease right-of-use assets

165,565

137,046

Deferred tax assets, net

111,578

82,707

Other long-term assets

78,314

29,680

Total assets

3,628,814

2,154,705

Liabilities and stockholders' equity

Current liabilities:

Accounts payable

501,297

143,278

Accrued liabilities

210,255

77,039

Deferred revenue

141,384

127,160

Deferred acquisition payable

537,381

1,479

Earn-out consideration

81,364

50,632

Operating lease liabilities

11,551

4,843

Total current liabilities

1,483,232

404,431

Convertible senior notes, net

1,365,299

972,580

Operating lease liabilities

169,389

143,167

Deferred acquisition payable

165,624

5,484

Earn-out consideration

81,600

53,009

Deferred tax liabilities, net

30,934

28,856

Other long-term liabilities

8,664

6,250

Total liabilities

3,304,742

1,613,777

Commitments and contingencies

Stockholders' equity:

Common stock – Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 224,920,310 and 218,867,898 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of June 30, 2026 and December 31, 2025

Additional paid-in capital

662,263

652,383

Accumulated other comprehensive (loss) income

(46,037)

2,294

Accumulated deficit

(292,177)

(113,772)

Total stockholders' equity

324,072

540,928

Total liabilities and stockholders' equity

3,628,814

2,154,705

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME

(In Thousands, Except Share and Per Share Data, Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Revenue

753,214

544,833

1,361,318

1,130,843

Cost of revenue

272,411

128,637

483,728

283,958

Gross profit

480,803

416,196

877,590

846,885

Gross margin %

Operating expenses:(1)

Marketing

262,236

217,862

484,239

449,097

Operations and support

95,481

66,490

191,984

129,523

Technology and development

54,901

37,848

101,837

67,762

General and administrative

165,377

67,273

275,045

115,883

Total operating expenses

577,995

389,473

1,053,105

762,265

(Loss) income from operations

(97,192)

26,723

(175,515)

84,620

Other income (expense):

Change in fair value of equity securities

4,737

—

(4,945)

—

Change in fair value of liabilities

(4,223)

—

(21,869)

—

Other income, net

4,045

6,130

8,145

8,728

Total other income (expense), net

4,559

6,130

(18,669)

8,728

(Loss) income before income taxes

(92,633)

32,853

(194,184)

93,348

Benefit from (provision for) income taxes

6,343

9,652

15,779

(1,358)

Net (loss) income

(86,290)

42,505

(178,405)

91,990

Other comprehensive (loss) income

(41,632)

986

(48,331)

1,146

Total comprehensive (loss) income

(127,922)

43,491

(226,736)

93,136

Net (loss) income per share attributable to common stockholders:

Basic

(0.37)

0.19

(0.78)

0.41

Diluted

(0.37)

0.17

(0.78)

0.37

Weighted average shares outstanding:

Basic

231,746,126

224,373,375

230,061,076

223,187,936

Diluted

231,746,126

256,779,292

230,061,076

251,894,929

______________

(1)Includes stock-based compensation expense as follows (in thousands):

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Marketing

3,004

3,435

5,819

6,209

Operations and support

7,016

4,579

13,129

7,585

Technology and development

6,645

5,247

12,635

9,292

General and administrative

25,451

22,465

47,395

37,498

Total stock-based compensation expense

42,116

35,726

78,978

60,584

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In Thousands, Unaudited)

Six Months Ended June 30,

2026

2025

Operating activities

Net (loss) income

(178,405)

91,990

Adjustments to reconcile net (loss) income to net cash provided by operating activities:

Depreciation and amortization

51,430

18,741

Stock-based compensation

78,978

60,584

Change in fair value of equity securities

4,945

—

Change in fair value of liabilities

21,869

—

Net accretion on securities

(338)

(1,060)

Benefit from deferred taxes

(23,338)

(10,346)

Impairment of long-lived assets

1,148

—

Amortization of debt discount and issuance costs

3,656

1,047

Non-cash operating lease cost

9,482

4,594

Non-cash acquisition-related costs

21,311

2,985

Non-cash restructuring and other related charges included within cost of revenue

28,462

—

Non-cash other

2,511

(1,315)

Changes in operating assets and liabilities:

Receivables, net

(328,987)

(654)

Inventory

(14,255)

(77,373)

Prepaid expenses and other current assets

(37,427)

Other long-term assets

(30,553)

(10)

Accounts payable

323,795

5,146

Accrued liabilities

89,526

11,737

Deferred revenue

2,960

23,132

Earn-out consideration

(7,058)

—

Deferred acquisition payable

472

—

Operating lease liabilities

(4,894)

(1,798)

Other long-term liabilities

620

—

Net cash provided by operating activities

53,417

89,973

Investing activities

Maturities of available-for-sale investments

116,232

60,569

Proceeds from sales of available-for-sale investments

350,762

—

Purchases of property, equipment, and intangible assets

(55,770)

(101,392)

Investment in website development and internal-use software

(12,808)

(7,961)

Acquisition of businesses, net of cash acquired

(318,108)

(5,100)

Purchases of equity securities

(11,217)

—

Net cash provided by (used in) investing activities

69,091

(53,884)

Financing activities

Proceeds from issuance of convertible senior notes, net of debt discount

390,425

970,000

Purchases of capped calls related to convertible senior notes

(36,748)

(47,800)

Proceeds from exercise of vested stock options

13,030

6,497

Payments for taxes related to net share settlement of equity awards

(62,324)

(62,475)

Proceeds from employee stock purchase plan

3,846

2,970

Payments for acquisition-related earn-out consideration

(43,682)

—

Payments for debt issuance costs

(671)

(3,041)

Net cash provided by financing activities

263,876

866,151

Foreign currency effect on cash and cash equivalents

(5,189)

1,270

Increase in cash, cash equivalents, and restricted cash

381,195

903,510

Cash, cash equivalents, and restricted cash at beginning of period

228,616

221,440

Cash, cash equivalents, and restricted cash at end of period

609,811

1,124,950

Reconciliation of cash, cash equivalents, and restricted cash

Cash and cash equivalents

609,811

1,124,582

Restricted cash

—

368

Total cash, cash equivalents, and restricted cash

609,811

1,124,950

Supplemental disclosures of cash flow information

Cash (received) paid for taxes, net of refunds

(2,663)

23,047

Cash paid for interest

1,735

—

Non-cash investing and financing activities

Purchases of property, equipment, and intangible assets included in accounts payable and accrued liabilities

16,666

16,954

Right-of-use asset obtained in exchange for lease liability

25,681

63,434

Contingent and deferred consideration and liabilities assumed in connection with acquisition of businesses

886,287

—

Deferred debt issuance costs included in accounts payable and accrued liabilities

—

249

Issuance of common stock in connection with asset acquisition

—

12,760

Common stock to be issued for asset acquisition indemnification holdback

—

6,380

Non-GAAP Financial Measures

In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (which is a non-GAAP financial measure), Adjusted EBITDA margin (which is a non-GAAP ratio), and Free Cash Flow (which is a non-GAAP financial measure), each as defined below. We also present Adjusted Gross Profit, Adjusted Marketing, Adjusted Operations and support, Adjusted Technology and development, Adjusted General and administrative (collectively, Adjusted Operating Expenses), and Adjusted Net (Loss) Income (each of which are non-GAAP financial measures). We use Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income, when taken together with the corresponding U.S. GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income is helpful to our investors as they are used by management in assessing the health of our business, our operating performance, and our liquidity.

However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures or ratios differently or may use other financial measures or ratios to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income as tools for comparison. Reconciliations are provided below to the most directly comparable financial measures stated in accordance with U.S. GAAP. Investors are encouraged to review our U.S. GAAP financial measures and not to rely on any single financial measure to evaluate our business.

Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. “Adjusted EBITDA” is defined as net (loss) income before legal contingencies that are considered non-recurring, stock-based compensation, depreciation and amortization, acquisition and transaction-related costs (which includes (i) consideration paid for employee and nonemployee compensation with vesting requirements incurred directly as a result of acquisitions, and (ii) transaction professional services), restructuring and other related charges that are considered non-recurring, change in fair value of liabilities, payroll tax expense related to stock-based compensation, impairment of long-lived assets, interest income and expense, net, change in fair value of equity securities, and income taxes. “Adjusted EBITDA margin” is defined as Adjusted EBITDA divided by revenue.

In the first quarter of 2026, we announced a strategic shift for our United States weight loss offering ("2026 US WL Announcement"). As a result, we evolved our United States weight loss offering to match our global approach towards providing access to branded GLP-1 medications, and offering access to compounded GLP-1 medications through our platform on a limited scale. In connection with the strategic shift, we revised our definition of Adjusted EBITDA to include restructuring and other related charges that are considered non-recurring, as we believe these costs are distinguishable from ongoing operating costs and do not reflect current or expected performance of our ongoing operations. These costs consist of inventory write-downs, third-party costs, and non-recurring employee compensation charges, all of which were incurred directly as a result of the 2026 US WL Announcement. Additional restructuring and other related charges were incurred in the second quarter of 2026, and to the extent that we incur further restructuring and other related charges in connection with the 2026 US WL Announcement in future periods,

these costs will be presented consistently with our current presentation. As we did not record any non-recurring restructuring and other related charges in prior years, prior period disclosures were not impacted.

In the second quarter of 2025, we revised our definition of Adjusted EBITDA to include payroll tax expense related to stock-based compensation, which comprises employer taxes incurred upon vesting of restricted stock units and upon exercise of nonqualified stock options. As a result of recent trends in our stock price, this amount was not considered significant for prior periods and, accordingly, prior period disclosures were not recast to conform to the current presentation.

Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted EBITDA. When evaluating our performance, you should consider Adjusted EBITDA in addition to, and not as a substitute for, other financial performance measures, including our net (loss) income and other U.S. GAAP results.

Net (Loss) Income to Adjusted EBITDA Reconciliation

(In Thousands, Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Revenue

753,214

544,833

1,361,318

1,130,843

Net (loss) income

(86,290)

42,505

(178,405)

91,990

Legal contingencies

47,500

—

62,500

—

Stock-based compensation

42,116

35,726

78,978

60,584

Depreciation and amortization

29,477

10,465

51,430

18,741

Acquisition and transaction-related costs

28,835

6,231

42,201

6,255

Restructuring and other related charges

4,626

—

38,114

—

Change in fair value of liabilities

4,223

—

21,869

—

Payroll tax expense related to stock-based compensation

2,022

3,078

4,889

3,078

Impairment of long-lived assets

1,148

—

1,148

—

Interest income and expense, net

(2,254)

(6,117)

(7,287)

(8,713)

Change in fair value of equity securities

(4,737)

—

4,945

—

(Benefit from) provision for income taxes

(6,343)

(9,652)

(15,779)

1,358

Adjusted EBITDA

60,323

82,236

104,603

173,293

Net (loss) income as a % of revenue

(11)

(13)

Adjusted EBITDA margin

Free Cash Flow is a key performance measure that our management uses to assess our liquidity. Because Free Cash Flow facilitates internal comparisons of our historical liquidity on a more consistent basis, we use this measure for business planning purposes. “Free Cash Flow” is defined as net cash (used in) provided by operating activities, less

purchases of property, equipment, and intangible assets and investment in website development and internal-use software in investing activities.

Some of the limitations of Free Cash Flow include (i) Free Cash Flow does not represent our residual cash flow for discretionary expenditures and our non-discretionary commitments, and (ii) Free Cash Flow includes capital expenditures, the benefits of which may be realized in periods subsequent to those in which the expenditures took place. In evaluating Free Cash Flow, you should be aware that in the future we will have cash outflows similar to the adjustments in this presentation. Our presentation of Free Cash Flow should not be construed as an inference that our future results will be unaffected by these cash outflows or any unusual or non-recurring items. When evaluating our performance, you should consider Free Cash Flow in addition to, and not as a substitute for, other financial performance measures, including our net cash (used in) provided by operating activities and other U.S. GAAP results.

Net Cash (Used In) Provided By Operating Activities to Free Cash Flow Reconciliation

(In Thousands, Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Net cash (used in) provided by operating activities

(35,939)

(19,117)

53,417

89,973

Purchases of property, equipment, and intangible assets in investing activities

(25,926)

(46,065)

(55,770)

(101,392)

Investment in website development and internal-use software in investing activities

(6,328)

(4,250)

(12,808)

(7,961)

Free Cash Flow

(68,193)

(69,432)

(15,161)

(19,380)

Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income are key performance measures that our management uses to assess our operating performance. Because Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income facilitate internal comparisons of our historical operating performance on a more consistent basis, we use these measures for business planning purposes. “Adjusted Gross Profit” is defined as gross profit adjusted for restructuring and other related charges included within cost of revenue. “Adjusted gross margin” is defined as Adjusted Gross Profit divided by revenue. “Adjusted Marketing” is defined as marketing expense adjusted for stock-based compensation. “Adjusted Operations and support” is defined as operations and support expense adjusted for stock-based compensation and restructuring and other related charges included within operating expenses. “Adjusted Technology and development” is defined as technology and development expense adjusted for stock-based compensation. “Adjusted General and administrative” is defined as general and administrative expense adjusted for legal contingencies, acquisition and transaction-related costs, and stock-based compensation. “Adjusted Net (Loss) Income” represents Net (Loss) Income adjusted for legal contingencies, acquisition and transaction-related costs, and restructuring and other related charges, net of related tax effects.

Some of the limitations of Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income include that they omit certain costs and charges, and therefore do not reflect all expenses that impact the corresponding U.S. GAAP results. In evaluating Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income, you should be aware that in the future we may incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income. When evaluating our performance, you should consider Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income in addition to, and not as a substitute for, other financial performance measures, including our net (loss) income and other U.S. GAAP results.

Gross Profit to Adjusted Gross Profit Reconciliation

(In Thousands, Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Revenue

753,214

544,833

1,361,318

1,130,843

Gross Profit

480,803

416,196

877,590

846,885

Restructuring and other related charges included within cost of revenue

—

28,462

—

Adjusted Gross Profit

480,803

416,196

906,052

846,885

Gross margin %

Adjusted gross margin %

Operating Expenses to Adjusted Operating Expenses Reconciliation

(In Thousands, Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Marketing

262,236

217,862

484,239

449,097

Stock-based compensation

(3,004)

(3,435)

(5,819)

(6,209)

Adjusted Marketing

259,232

214,427

478,420

442,888

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Operations and support

95,481

66,490

191,984

129,523

Stock-based compensation

(7,016)

(4,579)

(13,129)

(7,585)

Restructuring and other related charges included within operating expenses

(4,626)

—

(9,652)

—

Adjusted Operations and support

83,839

61,911

169,203

121,938

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Technology and development

54,901

37,848

101,837

67,762

Stock-based compensation

(6,645)

(5,247)

(12,635)

(9,292)

Adjusted Technology and development

48,256

32,601

89,202

58,470

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

General and administrative

165,377

67,273

275,045

115,883

Legal contingencies

(47,500)

—

(62,500)

—

Acquisition and transaction-related costs

(28,835)

(6,231)

(42,201)

(6,255)

Stock-based compensation

(25,451)

(22,465)

(47,395)

(37,498)

Adjusted General and administrative

63,591

38,577

122,949

72,130

Net (Loss) Income to Adjusted Net (Loss) Income Reconciliation

(In Thousands, Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Net (loss) income

(86,290)

42,505

(178,405)

91,990

Legal contingencies

47,500

—

62,500

—

Acquisition and transaction-related costs

28,835

6,231

42,201

6,255

Restructuring and other related charges

4,626

—

38,114

—

Tax effects of adjustments

(15,423)

—

(28,763)

—

Adjusted Net (Loss) Income

(20,752)

48,736

(64,353)

98,245

Contacts:

Investor Relations

Bill Newby

Investors@forhims.com

Media Relations

Abby Reisinger-Moley

Press@forhims.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Aug. 10, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Aug. 10, 2026

Entity Registrant Name

HIMS & HERS HEALTH, INC.

Entity Incorporation, State or Country Code

Entity File Number

001-38986

Entity Tax Identification Number

98-1482650

Entity Address, Address Line One

2269 Chestnut Street, #523

Entity Address, Postal Zip Code

94123

Entity Address, City or Town

San Francisco

Entity Address, State or Province

City Area Code

415

Local Phone Number

851-0195

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Class A common stock, $0.0001 par value

Trading Symbol

HIMS

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

Entity Central Index Key

0001773751

Amendment Flag

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration